Payment overview · 2025
General Payments
$334.64
17 reported records · 8 companies
Healthcare provider profile · identity verified
Maria Socorro Ambulo Geronimo, MD
Allopathic & Osteopathic Physicians|Internal Medicine · MATTHEWS, NC · NPI 1811097967
Verified facts
What the public records show
CMS Open Payments records show Maria Socorro Ambulo Geronimo, MD received $334.64 in general payments during 2025 across 17 reported records.
PFIZER INC. accounted for 25.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Ozempic, Paxlovid, Shingrix.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Shingrix by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 104 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $86.84 | 25.9% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $60.69 | 18.1% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $59.26 | 17.7% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $34.01 | 10.2% | 2 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $31.91 | 9.5% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $30.07 | 9.0% | 2 | 2025 |
| Phadia US Inc. | Unresolved — no canonical attribution shown | $17.03 | 5.1% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $14.83 | 4.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $334.64 | 17 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $60.69 | 3 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $60.69 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $46.36 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $46.36 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $39.78 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $34.01 | 2 | 2025 |
Source payment records
|
|||||
| SAPIEN 3 Ultra RESILIA Normalized: sapien 3 ultra resilia |
Device | Edwards Lifesciences Corporation | $31.91 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $21.01 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $21.01 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $21.01 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $19.48 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $19.48 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $19.47 | 1 | 2025 |
Source payment records
|
|||||
| ImmunoCAP Normalized: immunocap |
Device | Phadia US Inc. | $17.03 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $16.24 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $14.83 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $13.83 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 78 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 104 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 11 | exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 28 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
28 | 25 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
104 | 19 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
78 | 16 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
11 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 654 | 185 |
| Atorvastatin Calcium | Atorvastatin Calcium | 464 | 131 |
| Losartan Potassium | Losartan Potassium | 417 | 116 |
| Levothyroxine Sodium | Levothyroxine Sodium | 390 | 106 |
| Amlodipine Besylate | Amlodipine Besylate | 293 | 80 |
| Metformin Hcl Er | Metformin Hcl | 280 | 83 |
| Lisinopril | Lisinopril | 272 | 74 |
| Metoprolol Succinate | Metoprolol Succinate | 258 | 69 |
| Pantoprazole Sodium | Pantoprazole Sodium | 235 | 69 |
| Hydrochlorothiazide | Hydrochlorothiazide | 205 | 68 |
| Trazodone Hcl | Trazodone Hcl | 199 | 52 |
| Simvastatin | Simvastatin | 185 | 47 |
| Omeprazole | Omeprazole | 182 | 57 |
| Pravastatin Sodium | Pravastatin Sodium | 148 | 40 |
| Allopurinol | Allopurinol | 129 | 28 |
| Furosemide | Furosemide | 123 | 50 |
| Fluticasone Propionate | Fluticasone Propionate | 117 | 55 |
| Escitalopram Oxalate | Escitalopram Oxalate | 115 | 29 |
| Citalopram Hbr | Citalopram Hydrobromide | 109 | 28 |
| Ozempic | Semaglutide | 104 | 19 |
| Zolpidem Tartrate | Zolpidem Tartrate | 102 | 20 |
| Gabapentin | Gabapentin | 94 | 35 |
| Alprazolam | Alprazolam | 86 | 18 |
| Tramadol Hcl | Tramadol Hcl | 86 | 22 |
| Montelukast Sodium | Montelukast Sodium | 79 | 25 |
| Eliquis | Apixaban | 78 | 16 |
| Metoprolol Tartrate | Metoprolol Tartrate | 78 | 24 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 76 | 20 |
| Carvedilol | Carvedilol | 73 | 19 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 68 | 43 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 68 | 21 |
| Synthroid | Levothyroxine Sodium | 68 | 16 |
| Famotidine | Famotidine | 64 | 21 |
| Tizanidine Hcl | Tizanidine Hcl | 63 | 25 |
| Ezetimibe | Ezetimibe | 60 | 17 |
| Potassium Chloride | Potassium Chloride | 60 | 19 |
| Sertraline Hcl | Sertraline Hcl | 60 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 59 | 19 |
| Bupropion Xl | Bupropion Hcl | 55 | 18 |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 54 | 54 |
| Fluoxetine Hcl | Fluoxetine Hcl | 54 | 16 |
| Alendronate Sodium | Alendronate Sodium | 46 | 15 |
| Valacyclovir | Valacyclovir Hcl | 46 | 19 |
| Glimepiride | Glimepiride | 45 | 13 |
| Lorazepam | Lorazepam | 45 | 15 |
| Atenolol | Atenolol | 44 | 14 |
| Spironolactone | Spironolactone | 43 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 42 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 41 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 39 | 11 |
| Tamsulosin Hcl | Tamsulosin Hcl | 38 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 38 | 26 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 34 | 14 |
| Doxycycline Hyclate | Doxycycline Hyclate | 34 | 31 |
| Meloxicam | Meloxicam | 34 | 15 |
| Celecoxib | Celecoxib | 32 | 11 |
| Estradiol | Estradiol | 30 | 13 |
| Prednisone | Prednisone | 30 | 26 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 28 | 23 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 28 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 28 | 25 |
| Rizatriptan | Rizatriptan Benzoate | 27 | suppressed |
| Ondansetron Odt | Ondansetron | 26 | 13 |
| Mupirocin | Mupirocin | 25 | 17 |
| Doxazosin Mesylate | Doxazosin Mesylate | 24 | suppressed |
| Jardiance | Empagliflozin | 24 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 23 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 23 | 22 |
| Fluconazole | Fluconazole | 23 | 15 |
| Hydralazine Hcl | Hydralazine Hcl | 23 | suppressed |
| Metformin Hcl | Metformin Hcl | 23 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 22 | suppressed |
| Mirtazapine | Mirtazapine | 22 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 22 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 22 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 21 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 21 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 21 | suppressed |
| Verapamil Er | Verapamil Hcl | 20 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 18 | suppressed |
| Chlorthalidone | Chlorthalidone | 18 | suppressed |
| Pregabalin | Pregabalin | 18 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 18 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 18 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 17 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 17 | 16 |
| Amoxicillin | Amoxicillin | 16 | suppressed |
| Ibuprofen | Ibuprofen | 16 | suppressed |
| Ketoconazole | Ketoconazole | 16 | 13 |
| Donepezil Hcl | Donepezil Hcl | 15 | suppressed |
| Fenofibrate | Fenofibrate | 15 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 15 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 15 | suppressed |
| Xarelto | Rivaroxaban | 15 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 14 | 11 |
| Methylprednisolone | Methylprednisolone | 14 | 14 |
| Ondansetron Hcl | Ondansetron Hcl | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Finasteride | Finasteride | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Lovastatin | Lovastatin | 13 | suppressed |
| Minoxidil | Minoxidil | 13 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 13 | suppressed |
| Telmisartan | Telmisartan | 13 | suppressed |
| Valsartan | Valsartan | 13 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 11 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 11 | suppressed |
| Indapamide | Indapamide | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | 11 |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $334.64 · 17 records | PFIZER INC. | ABRYSVO, AREXVY, COMIRNATY, ELIQUIS, EVENITY, ImmunoCAP, JARDIANCE, KRYSTEXXA, Kerendia, NURTEC ODT, Ozempic, PAXLOVID, PREVNAR 20, Rybelsus, SAPIEN 3 Ultra RESILIA, SHINGRIX, Wegovy | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error